Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rush physicians using gene therapy for heart patients with moderate to severe chest pains

03.02.2005


Rush is Only Chicago Medical Center Among 20 U.S. Sites in Clinical Study



Individuals with moderate to severe chest pains (angina) who have not found relief from medication may benefit from a new gene therapy approach being used by cardiologists at Rush University Medical Center to grow new blood vessels in the heart.

The phase II clinical research study uses vascular endothelial growth factor-2 (VEGF-2) in the form of a solution containing a DNA plasmid that is delivered using catheterization to heart tissue that has been damaged from insufficient blood flow.


Once the catheter reaches the targeted site inside of the heart, the VEGF-2 is injected into the heart muscle region with inadequate blood supply. The DNA plasmid is then taken up by the middle muscular layer of the heart wall near the injection site. Inside the cell, the DNA encoded VEGF-2 expresses itself which in turn stimulates the growth of new blood vessels by promoting the proliferation of endothelial cells in the heart.

New blood vessels are required to provide oxygen-carrying blood to heart muscles to compensate for the blocked heart arteries. The subsequent, improved blood flow relieves the painful symptoms of angina.

"The process of growing new blood vessels, or angiogenesis, should occur over the course of four to eight weeks following the procedure which is done in the cardiac catheterization lab at Rush," said Dr. Gary L. Schaer, the principal investigator of the trial at Rush and director of the Rush Cardiac Catheterization Labs. "The patient goes home the next day." Several patients have received the gene therapy and all are doing well.

Individuals who may be candidates for this gene therapy study trial must have moderate to severe angina, but cannot also be candidates for treatment using angioplasty or bypass surgery. Angioplasty involves a catheterization with a balloon-like device that opens blocked arteries, while bypass surgery requires open-heart surgery to place veins removed from the patient’s leg or arteries taken from the patient’s chest wall or arm to "bypass" the blocked blood vessels.

While both of these treatments have been shown to be successful in relieving severe chest pains resulting from blocked arteries, a significant percentage of patients eventually do not respond well to either treatment, often requiring another angioplasty or bypass operation, noted Schaer. "If gene therapy proves to be safe and effective, it will represent an important new approach to improve the quality of life in these seriously ill patients with refractory chest pain," said Dr. R. Jeffrey Snell, study co-investigator and Schaer’s colleague at Rush.

In the new study, patients will be randomly assigned to receive the gene administered through a cardiac catheter threaded into the heart from a leg artery or a placebo delivered using the same method. As required by the U.S. Food and Drug Administration, the study is "double blinded," which means that neither the doctor nor the patient will know whether he or she is receiving the gene therapy or a placebo. For every three patients that receive the active gene, one will receive a placebo. Following treatment, patients enrolled in the study will be examined for chest pain at one month, three months and six months. A total of 404 patients will be enrolled in the study at the 20 study sites across the country.

The Genetic Angiogenic Stimulation Investigational Study (GENASIS) is funded by Corautus Genetics.

More than 11 million people in the United States suffer from coronary artery disease. Many patients receive medications to increase blood flow but nearly 500,000 angioplasties and coronary bypass procedures are performed each year in those patients who do not benefit from medication.

John Pontarelli | EurekAlert!
Further information:
http://www.rush.edu

More articles from Life Sciences:

nachricht Water world
20.11.2017 | Washington University in St. Louis

nachricht Carefully crafted light pulses control neuron activity
20.11.2017 | University of Illinois at Urbana-Champaign

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

Im Focus: Wrinkles give heat a jolt in pillared graphene

Rice University researchers test 3-D carbon nanostructures' thermal transport abilities

Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Antarctic landscape insights keep ice loss forecasts on the radar

20.11.2017 | Earth Sciences

Filling the gap: High-latitude volcanic eruptions also have global impact

20.11.2017 | Earth Sciences

Water world

20.11.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>